|
Trastuzumab and cardiac toxicity: monitoring in the adjuvant setting
Mary Babb Randolph Cancer Center, West Virginia University School of Medicine, Morgantown, WV
Although trastuzumab has been approved for use in patients with metastatic breast cancer, recent trials have shown a significant impact of adding trastuzumab to adjuvant therapy for patients with early breast cancer. A major limiting toxicity for trastuzumab is the potential to precipitate heart failure, particularly after anthracycline-based treatment. We have analyzed the phase III adjuvant trials to generate universal guidelines for trastuzumab treatment in patients with early breast cancer.
| Commun Oncol 2007;4:739–744 | full text |  159 kb |